Author

Tomoko Maeda‐Chubachi

Observed names: Maeda-Chubachi Tomoko, Maeda-Chubachi, Tomoko, T Maeda-Chubachi, T. Maeda-Chubachi, T. Maeda‐Chubachi, Tomoko Maeda-Chubachi

Observed institutions: Moorfields Eye Hospital NHS Foundation Trust, Inserm, Eli Lilly (United States), Pfizer (United States), University of Utah, North Carolina Biotechnology Center, NIHR Moorfields Biomedical Research Centre, GlaxoSmithKline (United States), Duke Medical Center, Novan Therapeutics (United States), Moorfields Eye Hospital, University College London

ORCID: 0000-0002-3614-1505

Observed ORCID: 0000-0002-3614-1505

OpenAlex ID: A5065619082

A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis

2018 · Johnny Peppers, Amy S. Paller, et al. · Journal of the American Academy of Dermatology · 171

Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis

2018 · Kevin Robbins, Robert Bissonnette, et al. · Journal of the American Academy of Dermatology · 98

Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink

2014 · E. Edson‐Heredia, B. Zhu, et al. · Journal of the European Academy of Dermatology and Venereology · 95

Heterogeneity of Response to Biologic Treatment: Perspective for Psoriasis

2013 · Emily Edson-Heredia, Kimberly L. Sterling, et al. · Journal of Investigative Dermatology · 86

PDF

Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial

2014 · B. Zhu, E. Edson‐Heredia, et al. · British Journal of Dermatology · 65

Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study

2018 · Robert Bissonnette, Lakshmi S. Vasist, et al. · Clinical Pharmacology in Drug Development · 42

Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative

2022 · Yael A. Leshem, Joanne R. Chalmers, et al. · JAMA Dermatology · 40

Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial

2022 · John C. Browning, Carolyn Enloe, et al. · JAMA Dermatology · 40

Efficacy and tolerability of an investigational nitric oxide–releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial

2019 · Adelaide A. Hebert, Elaine C. Siegfried, et al. · Journal of the American Academy of Dermatology · 40

PDF

Comparison of Latanoprost and Timolol in Pediatric Glaucoma: A Phase 3, 12-Week, Randomized, Double-Masked Multicenter Study

2011 · Tomoko Maeda-Chubachi, Katherine Chi-Burris, et al. · Ophthalmology · 40

A high level of clinical response is associated with improved patient‐reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab

2015 · E. Edson‐Heredia, S. Banerjee, et al. · Journal of the European Academy of Dermatology and Venereology · 34

Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys.

2015 · Emily Edson-Heredia, Baojin Zhu, et al. · PubMed · 33

Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials

2023 · Jeffrey L. Sugarman, Adelaide Hebert, et al. · Journal of the American Academy of Dermatology · 28

PDF

Understanding the Relationship Between Pruritus Severity and Work Productivity in Patients With Moderate-to-Severe Psoriasis: Sleep Problems Are a Mediating Factor.

2016 · A B Kimball, E Edson-Heredia, et al. · PubMed · 28

Latanoprost Systemic Exposure in Pediatric and Adult Patients with Glaucoma: A Phase 1, Open-Label Study

2011 · Susan Raber, Rachel Courtney, et al. · Ophthalmology · 27

SB206, a Nitric Oxide–Releasing Topical Medication, Induces the Beginning of the End Sign and Molluscum Clearance

2021 · Tomoko Maeda-Chubachi, David Hebert, et al. · JID Innovations · 23

PDF

A Phase 2 Controlled Study of SB206, a Topical Nitric Oxide-Releasing Drug for Extragenital Wart Treatment.

2018 · Stephen K Tyring, Theodore Rosen, et al. · PubMed · 19

A Nitric Oxide–Releasing Topical Medication as a Potential Treatment Option for Atopic Dermatitis through Antimicrobial and Anti-Inflammatory Activity

2020 · Emma Guttman-Yassky, Richard L. Gallo, et al. · Journal of Investigative Dermatology · 17

PDF

The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology

2023 · Brian M. Ward, Daniel A. Riccio, et al. · Viruses · 14

PDF

A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results

2022 · John Caleb Browning, Martina Cartwright, et al. · American Journal of Clinical Dermatology · 13

PDF

Pharmacokinetic Profile, Safety, and Tolerability of Topical Berdazimer Gel, 10.3% in Patients With Molluscum Contagiosum

2022 · Martina Cartwright, Carolyn Enloe, et al. · Journal of Drugs in Dermatology · 12

PDF

Impact of Age, Diagnosis, and History of Glaucoma Surgery on Outcomes in Pediatric Patients Treated With Latanoprost

2013 · Tomoko Maeda-Chubachi, Katherine Chi-Burris, et al. · Journal of Glaucoma · 11

Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis

2024 · Amy S. Paller, Lawrence J. Green, et al. · Pediatric Dermatology · 10

PDF

A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis.

2018 · Boni E Elewski, Leon H Kircik, et al. · PubMed · 6

The safety and tolerability of berdazimer gel 10.3% in Japanese patients with molluscum contagiosum

2024 · Makoto Kawashima, Yoshiyuki Kaneko, et al. · JAAD International · 5

PDF

Works count: 45

Citation count: 1,006

H-index: 17

I10-index: 23